This site is intended for US healthcare professionals
Alkermes logo
Alkermes logo
Educational Resources
Resources Home
Congresses
Product Information
Our Pipeline
Knowledge Vault
Contact an MSL
Medical Information
Research & Medical Grants

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

European Sleep Research Society
September 24th – 27th 2024, Seville, Spain
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted.
Narcolepsy
POSTER
The Orexin 2 Receptor Agonist ALKS 2680 in Patients With Idiopathic Hypersomnia: An Initial Proof of Concept Phase 1b Study
AUTHOR(S)

Brendon Yee,1 Ron Grunstein,1 Julia Chapman,1 Jian Eu Tai,1 Sheila Sivam,1 Craig Hopkinson,2 Jandira Ramos,2 Shifang Liu,2 Daniel Smith,2 Sergey Yagoda,2 Bhaskar Rege2
 

View poster
Narcolepsy
Narcolepsy
POSTER
The Orexin 2 Receptor Agonist ALKS 2680 in Patients With Narcolepsy Type 2 An Initial Proof of Concept Phase 1b Study
AUTHOR(S)

Ron Grunstein,1 Brendon Yee,1 Julia Chapman,1 Jian Eu Tai,1 Sheila Sivam,1 Craig Hopkinson,2 Jandira Ramos,2 Shifang Liu,2 Daniel Smith,2 Sergey Yagoda,2 Bhaskar Rege2

View poster
Narcolepsy
Narcolepsy
POSTER
Vibrance-1: Study Design and Methods for a Phase 2, Randomised, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Narcolepsy Type 1
AUTHOR(S)

David Plante,1 Ron Grunstein,2 Giuseppe Plazzi,3 Anne Marie Morse,4 Jandira Ramos,5 Shifang Liu,5 Sergey Yagoda,5 Bhaskar Rege5

View poster
Narcolepsy
Narcolepsy
POSTER
Vibrance-2: Study Design and Methods for a Phase 2, Randomised, Placebo-Controlled, Parallel Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Narcolepsy Type 2
AUTHOR(S)

David Plante,1 Ron Grunstein,2 Giuseppe Plazzi,3 Chad Ruoff,4 Jandira Ramos,5 Shifang Liu,5 Sergey Yagoda,5 Bhaskar Rege5

View poster
Narcolepsy
Contact Us Terms of Use Privacy Policy www.alkermes.com

The product information provided on this site is intended only for healthcare professionals in the United States and is for informational purposes only. This site is designed to provide background and scientific findings concerning Alkermes products and areas of therapeutic interest. Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.

If you have a suspected Adverse Event or Product Complaint to report, please contact us by phone at 888-235-8008 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Your use of this information is subject to the terms and conditions of our Privacy Policy.

© 2024 Alkermes, Inc. All rights reserved. MA-004230

Please review our Privacy Policy.

By using our website without changing your cookie settings you agree to our use of cookies as described in our Privacy Policy. Learn more.

Close
This site is intended for US healthcare professionals
Alkermes Logo
Educational Resources
Congresses
Product Information
Our Pipeline
Contact an MSL
Medical Information
Research & Medical Grants